RFK Jr.'s Peptide Push Could Spark $180B Wellness Boom—Here's Who Wins

Robert F. Kennedy Jr., the U.S. Health Secretary, is pushing to relax federal restrictions on peptides, a move that could spark a major wellness trend. The move may benefit telehealth companies, compounding pharmacies, and longevity clinics seeking the next big market opportunity.

Why Peptides Could Be the Next Wellness Boom

The heavily promoted but loosely regulated proteins could fuel a market surge similar to the boom seen with weight-loss drugs—despite limited evidence of their effectiveness in humans.

State of Play: Peptides Gain Popularity Among Consumers

Self-administered peptide injections have gained traction among fitness enthusiasts, celebrities, and consumers seeking injury healing, inflammation reduction, and anti-aging benefits. Social media influencers and podcasters, including Joe Rogan, have amplified interest. In February, Rogan hosted a segment where Kennedy previewed his agenda and revealed he had taken peptides himself.

FDA to Review Peptide Regulations in July

The Food and Drug Administration (FDA) will convene an advisory panel in July to decide whether compounding pharmacies can produce certain peptides. The agency is also lifting a Biden administration policy that previously prohibited compounding pharmacies from manufacturing these products.

Among the substances under review is BPC-157, a peptide derived from human gastric juice and widely promoted for injury healing in animal studies.

Industry Experts Weigh In on Peptide Potential

"They're the most potent things that we've seen in health care since hormones."

Chris Shade, CEO of Quicksilver Scientific, which produces oral peptide versions

However, physicians warn of potential health risks, including cancer, due to peptides' effects on hormone production and tissue formation. Concerns also extend to the safety of taking multiple peptides simultaneously and their interactions with other drugs.

"The FDA should ban these peptides from being imported, from being used, and force the companies that are making huge amounts of profit on them to do the proper studies."

Eric Topol, Executive Vice President of Scripps Research

Market Projections: Peptides Could Reach $180B in Five Years

Peptides already constitute a $60 billion market and could exceed $180 billion within five years if federal rules are relaxed, according to Kate Festle, Managing Director at West Monroe Consultants.

"I think this has tremendous staying power because a lot of the companies that ... would be able to bundle this already exist. They have scale, they have membership."

Kate Festle, Managing Director at West Monroe Consultants

Winners in the Peptide Market: Telehealth and Longevity Clinics

Telehealth companies like Hims & Hers and Ro are poised to benefit, as they already have the infrastructure to prescribe and package peptide therapies quickly. Hims acquired a peptide manufacturing facility last year, and its shares surged nearly 50% in a week following the FDA's anticipated changes.

High-end wellness and longevity clinics may also gain, as many have already acquired compounding pharmacies to control the value chain, Festle noted.

Understanding Peptides: The Science Behind the Trend

Peptides are short chains of amino acids, a category that includes GLP-1s. This inclusion is one reason these products are rapidly gaining mainstream acceptance. Festle added that the expansion of direct-to-consumer channels for anti-obesity drugs has made patients more comfortable seeking treatments without consulting a doctor.

However, the lack of rigorous human studies on peptides raises concerns about their safety and efficacy.